LetibotulinumtoxinA is a purified type A botulinum neurotoxin protein complex used to improve the appearance of glabellar lines. The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s.
- Mechanism
- Curator reviewed · 5 references
LetibotulinumtoxinA, like other botulinum toxins, exerts its therapeutic effects via action directly on motor neurons. The toxin heavy chain mediates binding to surface receptors on nerve endings, after which the toxin is internalized via receptor-mediated endocytosis. The toxin light chain is subsequently translocated into the cytosol where it cleaves SNAP25, a cytosolic protein that forms a portion of the SNARE complex involved in vesicle fusion prior to exocytosis. The cleavage of SNAP25 prevents the formation of the SNARE complex, which subsequently prevents the exocytosis of acetylcholine into the neuromuscular junction, thereby inducing flaccid paralysis of the affected muscle(s).
- Primary indication
- LetibotulinumtoxinA is indicated for the temporary improvement of the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ≤65 years of age.Curator reviewed · 2 structured indications
- First approval
- Canada, 2024 · United States, 2024
Resolves to
What you can answer from here — as of March 03, 2026
Which drugs share a target with LetibotulinumtoxinA, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account